Related Experiment Videos
Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
Albert W Chan1, Martin J Quinn, Deepak L Bhatt
1Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Insights
Beta-blockers significantly improve long-term survival after successful percutaneous coronary intervention (PCI). This study found a marked survival benefit in patients receiving beta-blocker therapy post-PCI.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Beta-blockers are known to reduce mortality post-myocardial infarction (MI).
- Limited data exist on their efficacy after successful percutaneous coronary intervention (PCI).
Purpose of the Study:
- To evaluate the mortality benefit of beta-blockers in patients who have undergone successful PCI.
- To assess the long-term survival advantage conferred by beta-blocker therapy in this population.
Main Methods:
- A prospective registry of 4,553 patients undergoing PCI between 1993-1999 was analyzed.
- Patients with acute MI, shock, or unsuccessful revascularization were excluded.
- Multivariate survival analysis with propensity analysis adjusted for group heterogeneity.
Main Results:
- 45% of patients received beta-blockers. Beta-blocker therapy was linked to a mortality reduction from 6.0% to 3.9% at one year (p=0.0014).
- This survival benefit was independent of left ventricular function, diabetes, hypertension, or prior MI history.
- Propensity analysis confirmed beta-blocker use as an independent predictor of one-year survival (HR 0.63, p=0.0054).
Conclusions:
- Beta-blocker use is associated with a significant long-term survival benefit.
- This benefit is observed in patients undergoing successful elective percutaneous coronary revascularization.
Objectives:
The goal of this study was to evaluate the mortality benefit of beta-blockers after successful percutaneous coronary intervention (PCI).
Background:
Beta-blockers reduce mortality after myocardial infarction (MI), though limited data are available regarding their role after successful PCI.
Methods:
Each year from 1993 through 1999, the first 1,000 consecutive patients undergoing PCI were systematically followed up. Patients presenting with acute or recent MI, shock, or unsuccessful revascularization procedures were excluded from the analysis. Clinical, procedural, and follow-up data of beta-blocker-treated and non-beta-blocker-treated patients were compared. A multivariate survival analysis model using propensity analysis was used to adjust for heterogeneity between the two groups.
Results:
Of the 4,553 patients, 2,056 (45%) were treated with beta-blockers at the time of the procedure. Beta-blocker therapy was associated with a mortality reduction from 1.3% to 0.8% at 30 days (p = 0.13) and a reduction from 6.0% to 3.9% at one year (p = 0.0014). This survival benefit of beta-blockers was independent of left ventricular function, diabetic status, history of hypertension, or history of MI. Using propensity analysis, beta-blocker therapy remained an independent predictor for one-year survival after PCI (hazard ratio, 0.63; 95% confidence interval, 0.46 to 0.87; p = 0.0054).
Conclusions:
Within this large prospective registry, beta-blocker use was associated with a marked long-term survival benefit among patients undergoing successful elective percutaneous coronary revascularization.